Spirit AeroSystems Reports Third Quarter 2024 Results
WICHITA, Kan., Oct. 23, 2024 /PRNewswire/ — Third Quarter 2024 Revenues of $1.5 billionEPS of $(4.07); Adjusted EPS* of $(3.03)Cash used in operations of $276 million; Free cash flow* usage of $323 million Spirit AeroSystems Holdings, Inc. (NYSE: SPR) (“Spirit,” “Spirit AeroS
GRAFF FOR NATION: REVIVING MASTERPIECES WITH GRAFFITI ART IN LANGKAWI
LANGKAWI, Malaysia, Oct. 23, 2024 /PRNewswire/ — The Ministry of Tourism, Arts, and Culture (MOTAC), through its agency, the National Art Gallery Malaysia, is proud to announce the upcoming ‘Graff for Nation’ event, taking place from 25th to 29th October 2024, at the Kuah Old Hospi
DAISO NEW STORE OPENING IN VACAVILLE, CALIFORNIA
VACAVILLE, Calif., Oct. 23, 2024 /PRNewswire/ — Daiso, the renowned global retail chain offering a wide range of affordable and unique products, is thrilled to announce the grand opening at Nut Tree in Vacaville, California on November 2nd. “We are thrilled to open our store at Nut Tree
DAISO NEW STORE OPENING IN SAN ANTONIO, TEXAS
SAN ANTONIO, Oct. 23, 2024 /PRNewswire/ — Daiso, the renowned global retail chain offering a wide range of affordable and unique products, is thrilled to announce the grand opening at Westover Marketplace in San Antonio, Texas on November 2nd. “We are thrilled to open our store at Westo
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER’S DISEASE CONFERENCE (CTAD)
TOKYO, Oct. 23, 2024 /PRNewswire/ — Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) proto
PL Developments Announces Early Tender Time Results for the Previously Announced Exchange Offer
WESTBURY, N.Y., Oct. 23, 2024 /PRNewswire/ — P & L Development Holdings, LLC (“PLD” or the “Company”) today announced the early participation results of certain of its subsidiaries’ previously announced offer to exchange (the “Exchange Offer”) up t
PL Developments Announces Early Tender Time Results for the Previously Announced Exchange Offer
WESTBURY, N.Y., Oct. 23, 2024 /PRNewswire/ — P & L Development Holdings, LLC (“PLD” or the “Company”) today announced the early participation results of certain of its subsidiaries’ previously announced offer to exchange (the “Exchange Offer”) up t
EISAI TO PRESENT UPDATED DUAL-ACTING LECANEMAB DATA, RESEARCH ON BLOOD BIOMARKERS FOR PREDICTING PRESENCE OF AMYLOID IN THE BRAIN AND NEW FINDINGS ON THE ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 AT THE 17TH CLINICAL TRIALS FOR ALZHEIMER’S DISEASE CONFERENCE (CTAD)
TOKYO, Oct. 23, 2024 /PRNewswire/ — Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings on its Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (Aβ) proto
Spirit AeroSystems Reports Third Quarter 2024 Results
WICHITA, Kan., Oct. 23, 2024 /PRNewswire/ — Third Quarter 2024 Revenues of $1.5 billion EPS of $(4.07); Adjusted EPS* of $(3.03) Cash used in operations of $276 million; Free cash flow* usage of $323 million Spirit AeroSystems Holdings, Inc. (NYSE: SPR) (“Spirit,” “Spirit Aer
Genomma Lab Internacional Announces Results for the Third Quarter 2024
MEXICO CITY, Oct. 23, 2024 /PRNewswire/ — Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma” or “the Company”), today announced its results for the second quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prep
